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Abbreviations 
ADE antibody-dependent enhancement 
alum  aluminum hydroxide 
BCRs B cell receptors 
C capsid 
CHIKV  Chikungunya virus 
CSP circumsporozoite protein 
DENV Dengue virus 
E envelope 
ED envelope domain 
ELISA enzyme-linked immunosorbent assay 
EM  electron microscopy 
ER endoplasmic reticulum  
FRNT50 50% focus reduction neutralization test 
GC germinal center 
GFP green fluorescent protein 
HBc hepatitis B virus core protein 
HRP horseradish peroxidase 
i.m. intramuscularly 
JEV  Japanese encephalitis virus 
NAb neutralizing antibody  
NANP  Asn-Ala-Asn-Pro [NANP] repeat region in CSP 
OD optical density 
PBS phosphate-buffered saline 
prM precursor membrane 
PRNT50 50% plaque reduction neutralization test 
qPCR quantitative PCR 
rE recombinant E proteins  
ST/TM stem and transmembrane anchor 
VLP virus-like particle  
ZIKV  Zika virus 
αVLP An epitope insertable VLP produced from vector encoding CHIKV 
structural proteins (C-E3-E2-6K-E1) with a short linker introduced in E2 
E3αVLP A VLP produced from an expression vector for E3E2 cleavage-impaired 
αVLP by mutating the furin recognition site 
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General Introduction 
 Vaccines are biological products that provide immunity to the recipient against 
specific pathogen, and it have been successful for over 100 years in preventing and reducing 
the burden of infectious diseases1. However, still there are many pathogens against which 
vaccines do not exist. Most of vaccines developed in the past were made from live-attenuated 
strains of pathogen (live attenuated vaccine). In general, the live attenuated vaccines are 
highly immunogenic but possess safety concerns that remain the possibilities of reversing 
into disease causing viruses. Other traditional vaccines, inactivated pathogen (Inactivated 
vaccine) or recombinant pathogen protein (subunit vaccine) are known to be less 
immunogenic than the live attenuated vaccine in most cases2.  
 Virus-Like Particles (VLPs) emerged as novel vaccines that provide potency and 
safety at the same time. VLPs are self-assembled particles consisting of viral structural 
proteins, which mimic the conformation of the authentic native virus but lack its genomic 
DNA or RNA3. When presented within a host immune system, VLPs evoke effective immune 
responses without triggering the side effects associated with the native virus. Several VLP-
based vaccines are successful, including vaccines against hepatitis B virus and human 
papillomavirus4. More than 110 viruses are reported to produce VLP by various production 
systems include E.coli, yeast, insect cells or mammalian cells3. However, VLPs cannot be 
created from any virus easily. In the chapter 1 in this thesis, I tried to produce the dengue 
virus VLP, which was known to be difficult to create, by modifying their structural proteins 
in terms of the structure and the function of it. 
 In addition to the use of VLPs as the direct immunogens, the efficacy with which 
stimulate the immune responses make the VLPs as the carrier molecules for the delivery of 
epitopes of external target1. Those epitopes can be inserted either by chemical conjugation of 
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epitope with VLP, or genetic insertion of target sequences into viral structural proteins. In 
chapter 2, I chose an alphavirus as a candidate of vaccine platform and tried it to add more 
characteristics.  
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Chapter 1: Development of VLP-based dengue vaccine  
1.1 Introduction 
 Dengue is a mosquito-borne viral disease that is rapidly spreading, making it one of 
the most serious public health problems worldwide. Dengue virus (DENV) is a positive-
strand RNA virus that belongs to the Flavivirus genus of the Flaviviridae family. There are 
four DENV serotypes cocirculating in areas of endemicity, and they share 60 to 75% identity 
at the amino acid level but are clinically indistinguishable5. Infection by any of the four 
serotypes of DENV causes dengue fever, which is a flu-like febrile illness, and occasionally 
progresses to life-threatening dengue hemorrhagic fever or dengue shock syndrome6. About 
50% of the world’s population is currently at risk of DENV infection7. There remains no 
effective dengue-specific antiviral treatment or therapy, and vector control efforts to prevent 
the spread of DENV have been ineffective8. Therefore, an effective vaccine is viewed as one 
of the most desired methods for controlling this disease. 
 A major challenge in dengue vaccine development is the existence of four closely 
related DENV serotypes. After an initial infection with one DENV serotype, individuals who 
are subsequently exposed to any of the other serotypes are more likely to develop a more 
severe case of the disease due to a phenomenon known as antibody-dependent enhancement 
(ADE); it has been reported that non-neutralizing levels of anti-DENV antibody can enhance 
viral entry into host cells by forming a DENV-antibody complex9-11. There is a concern that 
an incomplete immune response upon first immunization may cause ADE-mediated severe 
dengue disease during the period between the first and the last immunizations. Hence, there is 
a need for a safe and highly efficacious dengue vaccine that provides long-lasting immunity 
against all four serotypes simultaneously, with a short immunization schedule. Currently, 
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there is only one licensed dengue vaccine, Dengvaxia, developed by Sanofi Pasteur. This 
vaccine is a live attenuated tetravalent chimeric dengue vaccine made from the yellow fever 
attenuated 17D strain and DENV12. However, long-term safety and efficacy analysis of 
Dengvaxia revealed that those naïve to DENV at the time of vaccination have an increased 
risk of more severe cases of the disease upon dengue infection10,11. Although the precise 
mechanism is unknown, there is a concern for the ADE-mediated severe dengue cases in 
Dengvaxia13,14. In 2017, the manufacturer announced the recommendation that the vaccine 
only be used in people who have previously had a dengue infection as otherwise there was 
evidence it may worsen subsequent infections. 
 VLP-based vaccine is a feasible alternative to live attenuated vaccines because they 
are highly immunogenic, since they resemble the morphology of the authentic virus, have a 
good safety profile, and can be manufactured in a short time with affordable costs. Another 
advantage of using VLPs to develop a dengue vaccine include a short vaccination schedule, 
which will reduce the risk of ADE-mediated severe dengue cases. Furthermore, a multivalent 
VLP-based dengue vaccine is expected to elicit balanced antibody responses against all four 
DENV serotypes, as there is no concern for replication interference, which is a key issue for a 
live attenuated dengue vaccine15.  
 It has been reported that the co-expression of flavivirus precursor membrane (prM) 
and envelope (E) produces VLPs, with several reports on DENV VLP production in insect, 
yeast, and mammalian cells published by various groups; however, DENV VLP production 
levels were relatively low16-21. For our study, we created novel DENV VLPs for all four 
serotypes and produced them at high yields by introducing mutations into the E protein. 
Tetravalent vaccination with DENV VLPs elicited high titers of neutralizing antibody (NAb) 
against all four serotypes simultaneously in mice. Our tetravalent DENV VLP vaccine thus 
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bears the potential to serve as a next-generation dengue vaccine and as a template for other 
flavivirus vaccine development strategies. 
 
1.2 Results 
1.2.1 Amino acid mutation that increase DENV1-4 VLPs yield  
 The DENV genome encodes three structural proteins (capsid [C], prM, and E) that 
form the virus coat and seven nonstructural proteins that take part in virus replication within 
host cells. The complex of prM and E plays important roles in virus assembly and fusion to 
the host cell membrane. The E protein lies on the surface of the dengue virion and plays a 
direct role in cell entry, and it is thus recognized as a target for dengue vaccine 
development22. We created a DENV1 prM-E expression plasmid containing the hydrophobic 
signal sequence (ss; located between the C and prM genes) and the prM and E genes of 
DENV1 (Fig. 1A). When the plasmid was transfected into 293F cells, DENV1 prM-E VLPs 
were secreted into the culture supernatant. However, the amount of VLPs in the supernatant 
was very low as measured by Western blotting using an anti-DENV1 to 4 E (anti-DENV1-4 
E) monoclonal antibody (Fig. 1B, middle lane). 
 To overcome the low yield, we focused on modifying DENV E because the DENV E 
protein undergoes structural conformational changes when the dengue virion fuses with the 
host cell membrane. In a previously reported work on alphavirus VLP vaccine development, 
it was shown that mutating the E2 protein in the region of the conformational change greatly 
increased the VLP yield23. Since flaviviruses and alphaviruses both use mechanisms of class 
II fusion proteins for viral entry24, we hypothesized that a modification to the amino acid(s) 
which effects an E protein conformational change may also increase the DENV VLP yield.  
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Fig. 1. Development of DENV1 VLP.  
(A) Schematic illustration of the DENV genome and DENV1 VLP-expression vectors. C; 
Capsid, ss; signal sequence, prM; precursor membrane protein, E; Envelope. (B) Western 
blot analysis of DENV1 VLP-containing culture supernatant. 293F cells were transfected 
with control vector or expression plasmids encoding wild type DENV1 prM-E (prM-E) or 
prM-E with F108A mutation (prM-EF108A), and cultured for 4 days. Secreted DENV1 VLP 
was detected using a mouse anti-dengue1-4 E monoclonal antibody. The intensities for 
each band were measured and the relative intensity was calculated by setting the intensity 
of prM-E as 1.0. 
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 Based on the reports or literatures25-27, we selected 27 amino acids (aa) that could 
potentially affect the conformational change of the DENV1 E protein, introduced a single 
amino acid mutation for each residue, and assessed VLP production levels in culture 
supernatants (Table 1). As a result, we found that mutation of phenylalanine 108 to alanine 
(F108A) greatly increased the DENV1 VLP production. The production of DENV1 prM-
EF108A VLPs (here called DENV1 VLPs) was about 16-fold higher than that of wild-type 
DENV1 prM-E VLPs (Fig. 1B). 
  
 
 F108 is located in the fusion loop structure of the DENV E protein, which consists of 
hydrophobic amino acids and is responsible for the insertion of DENV E protein into the host 
cell membrane22. As this sequence is highly conserved among flaviviruses, we expected that 
the F108A mutation would also increase the production of other serotypes of DENV VLPs. 
Hence, we first constructed expression plasmids encoding DENV2 prM-E with or without the 
F108A mutation (Fig. 2A, DENV2 prM-EF108A and prM-E). However, when they were 
DENV1 prM-E VLP secretion DENV1 prM-E VLP secretion DENV1 prM-E VLP secretion
Wild type + K110Q - K246E -
K64S + K118M - K246R -
K64V - K120T - K246N -
R73A - K203N ++ K246V -
R93A - K204N - K246A +
R99Q - K210N - K246T +
R99M + H244A - K246M ++
W101F - H244F - K247N -
L107A - H244Y -
F108A +++ H244R -
Table.1. VLP secretion of DENV1 prM-E mutants into culture supernatant.  
DENV1 VLP was detected using mouse anti-dengue1-4 E monoclonal antibody. The 
intensities for each band were measured and the relative intensity was calculated by 
setting the intensity of wild type DENV1 prM-E was 1.0.  
- : no DENV1 VLP was detected in culture supernatant by Western Blotting with using 
anti- DENV E antibody. 
+ : equal or less than 1 fold ,  ++ : 1.1 to 3 fold, +++: more than 3 fold VLP production 
compared to wild- type DENV1 prM-E.  
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transfected into 293F cells, DENV2 prM-E and prM-EF108A did not secrete VLPs into the 
culture supernatant as measured by Western blotting using an anti-DENV2 E polyclonal 
antibody (Fig. 2B). The DENV2 E protein is 495 aa long and has structurally distinct 
domains, namely, envelope domain (ED)I, EDII, EDIII, and the stem and transmembrane 
anchor (ST/TM) region22. It has been thought that the ST/TM region contains a membrane 
retention signal which might contribute to the inefficient secretion of prM-E VLPs28. To 
facilitate DENV2 VLP secretion, we next created a chimeric DENV2 construct by replacing 
the C-terminal region of DENV2 E protein with the corresponding region of DENV1 E 
protein. We prepared several chimeric DENV2 E proteins with C-terminal regions of 
different lengths and assessed their VLP production in 293F cells. We found that replacing aa 
297 to 495 of the DENV2 E protein, which correspond to the whole EDIII and ST/TM 
region, with DENV1 E protein aa 297 to 495 enabled efficient DENV2 VLP production (Fig.  
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Fig. 2. Development of DENV2 VLP.  
(A) Schematic illustration of DENV2 VLP expression vectors. prM-E; wild type sequence 
of DENV2 prM-E, prM-EF108A; prM-E with F108A mutation, chimera 1-4: Chimeric 
DENV2 E constructs that have F108A mutation and different length of DENV1 E at C-
terminal region. prM-E_2/1; DENV2 E protein aa.297-495 region was substituted with 
corresponding region of DENV1 E protein, prM-EF108A_2/1: prM-E_2/1 with F108A 
mutation. EDIII: envelope domain III, ST/TM; stem and transmembrane anchor. (B, C) 
Western blot analysis of the DENV2 VLPs in the culture supernatant. Expression vectors 
were transfected into 293F cells and culture supernatant were tested for VLP production 
on day 4 by using goat anti-DENV2 E polyclonal antibody. Representative images from at 
least 3 independent experiments are shown. (B) Effects of F108A mutation in prM-E or 
prM-E_2/1. The intensities for each band were measured and the relative intensity was 
calculated by setting the intensity of comparing prM-E_2/1 as 1.0. (C) Effects of 
substituting length of DENV2 C-terminal region on VLP production. 
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2C, prM-EF108A_2/1). The amount of secreted VLPs with the F108A mutation (prM-
EF108A_2/1) was about 15-fold higher than that of VLPs without F108 mutation (prM-E_2/1) 
(Fig. 2B). Next, we used the same approach to produce DENV3 and DENV4 VLPs. Similar 
to the results for DENV2, the expression plasmids encoding DENV3 and DENV4 prM-E or 
prM-EF108A did not secrete VLPs into the culture supernatants (Fig. 3A and B). In DENV3, 
VLP production was greatly increased when the EDIII and ST/TM region of DENV3 E 
protein was replaced with aa 297 to 495 of DENV1 E protein (prM-E_3/1), and it was further 
enhanced by introducing the F108A mutation (Fig. 3A, prM-EF108A_3/1). Similar to the 
DENV2 VLP result, the production of DENV4 VLPs with the F108A mutation and EDIII 
and ST/TM replacement (prMEF108A_4/1) was about 14-fold higher than that of VLPs without 
F108 mutation (prM-E_4/1) (Fig. 3B). 
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Fig. 3. Development of DENV3 and DENV4 VLP.  
(A, B) Upper: Schematic illustration of VLP expression vectors. Lower: Western blot 
analysis of the DENV3 or DENV4 VLPs in the culture supernatant. Expression vectors 
were transfected into 293F cells and culture supernatant were tested for VLP production on 
day 4 by using antibodies against DENV1-4 E (A) or DENV4 E. (B). The intensities for 
each band were measured and the relative intensity was calculated by setting the intensity of 
comparing VLP as 1.0.  
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1.2.2 Production and characterization of DENV1-4 VLPs 
 DENV1-4 VLPs were expressed in 293F cells and purified from culture supernatants 
by utilizing a combination of anion-exchange column and ceramic hydroxyapatite column 
chromatography. The purified DENV1-4 VLP samples contained E (53 kDa) and prM 
(around 20 kDa) as major proteins when they were assessed by SDS-PAGE and Coomassie 
blue staining (Fig. 4A). The VLP yields after the purification steps, as determined by the 
Bradford protein assay were in the range of 0.5 to 3 mg/liter culture. Transmission electron 
microscopy (EM) images confirmed that DENV1-4 VLPs exhibited electron-dense 35- to 50-
nm spherical particles (Fig. 4B), which are similar in size to previously described DENV 
VLPs17,20,29 but smaller than dengue virions, which have a diameter of around 50 nm25. 
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Fig.4. Characterization of DENV VLPs.  
(A) SDS-PAGE analysis of purified DENV1-4 VLPs. Separated proteins were stained 
by Coomassie Blue dye. (B) Transmission electron microscopy images of purified 
DENV1-4 VLPs.  
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1.2.3 Immunogenicity and neutralizing antibody responses in mice induced by 
VLP vaccines 
 To evaluate the immune responses induced by DENV VLPs, BALB/c mice were 
immunized with 20 µg of monovalent DENV VLPs of each serotype or 20 µg of recombinant 
E proteins (rEs; aa 46 to 413) with aluminum hydroxide (alum) adjuvant intramuscularly 
(i.m.) three times at 3-week intervals. Two weeks after the last immunization, serum anti-
flavivirus IgG titers were measured by an enzyme-linked immunosorbent assay (ELISA), 
using purified Japanese encephalitis virus (JEV) antigen30. In comparison to the phosphate-
buffered saline (PBS) control group, mice immunized with rEs elicited anti-flavivirus 
antibodies. VLPs induced significantly higher anti-flavivirus IgG titers than those elicited by 
rEs (Fig. 5A). NAb titers against DENV1 to -4 were determined by the 50% focus reduction 
neutralization test (FRNT50)31. NAb titers induced by DENV rEs were below the detection 
limit except in the case of mice immunized with DENV2 rE. On the other hand, DENV VLPs 
induced high NAb responses against their homologous DENV serotype (Fig. 5B to E). The 
NAbs induced by DENV VLPs were serotype cross-reactive, but no cross-reactivity to JEV 
was detected. 
 We next evaluated the immunogenicity of DENV VLPs in a tetravalent formulation, 
which is a mixture of four vaccines against four individual antigens. BALB/c mice were 
immunized with PBS or 80 µg of DENV1-4 VLPs (20 µg per serotype) with alum adjuvant 
three times at 3-week intervals. We also compared the immunogenicity of DNA vaccines to 
that of the VLP vaccine by immunizing mice with plasmid DNA encoding wild-type DENV 
prM-E (DNA_wild type) or encoding our DENV VLPs containing the F108A mutation 
and/or chimeric E (DNA_F108A). Eighty micrograms of tetravalent DNA plasmids (20 µg 
per serotype) was administered by i.m. injection with electroporation as described 
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previously32. The tetravalent DNA vaccine encoding DENV VLPs (DNA_F108A) induced 
higher immune responses than those with the DNA vaccine  
  
Fig. 5. Immunogenicity and neutralizing activity of monovalent DENV VLPs.  
6-week-old female BALB/c mice (n=4) were immunized intramuscularly with PBS, 20 
µg of DENV VLP, or recombinant dengue E protein (rE) together with Alum three 
times at 3-week intervals. Serum was collected two weeks after the last immunization. 
(A) Serum anti-flavi IgG titer was determined by ELISA. Mean log10 ELISA titers 
(mean ± SD) are shown. Mann–Whitney U test in homologous serotype of DENV rE 
and VLP, where *; P < 0.05. (B-E) Serum neutralization titers of rE- or DENV VLP-
immunized mice against DENV1-4 and JEV. Each symbol represents the FRNT50 titer 
from an individual mouse, and the geometric mean titers are represented by horizontal 
bars. Open and filled symbols indicate DENV rE and VLP immunization, respectively. 
Mann–Whitney U test in homologous serotype of DENV rE and VLP, where *; P < 
0.05, ns; not significant.  
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encoding wild-type prM-E (DNA_wild type). The mice immunized with tetravalent VLPs 
demonstrated the highest anti-flavivirus IgG titers among the three groups (Fig. 6A). 
Moreover, tetravalent VLPs elicited a highly potent NAb response (Fig. 6B). Geomean 
FRNT50 titers against the four DENV serotypes in tetravalent VLP-immunized mice were 
7,479 (DENV1), 2,131 (DENV2), 3,202 (DENV3), and 869 (DENV4). The NAb response 
was not detected in the DNA_wild type group (FRNT50 titers were below the detection limit 
of 80). The DNA_F108A group showed substantial NAb responses, but the FRNT50 titers 
were significantly lower, less than 11% of those elicited in the VLP-immunized group. These 
data suggest that DENV VLP vaccine is a more effective vaccine form than the DNA vaccine 
format for the induction of potent NAbs. 
 Next, we tested the infection-enhancing capacity of antibodies elicited by DENV VLP 
immunization. Preexisting, non-neutralizing anti-DENV antibody can enhance viral entry 
into host cells by forming DENV-antibody complexes33. This phenomenon is known as ADE. 
To assess ADE activity, we utilized the Fc gamma receptor (Fc𝛄-expressing BHK cell 
system34. Sera from mice immunized with DENV DNA vaccines, both DNA_wild type and 
DNA_F108A, enhanced DENV infection 2- to 3-fold at a 1:10 serum dilution, demonstrating 
that the induced antibodies possessed ADE activity toward DENV (Fig. 7). In contrast, we 
did not observe infection enhancement for any of the four serotypes in sera from VLP-
immunized mice at a 1:10 serum dilution. When the sera from VLP immunized mice were 
diluted more than 1:100, infection enhancement was observed as expected, although no 
enhancement against DENV1 was observed in the dilutions we tested. 
 Taken together, these results demonstrated that our DENV1-4 VLPs were highly 
immunogenic and that our tetravalent DENV VLP vaccine elicited potent NAb responses 
against all four DENV serotypes simultaneously. 
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Fig. 6. Immunogenicity and neutralizing activity of tetravalent DNA or VLP 
vaccines.  
6-week-old female BALB/c mice (n=4) were immunized with 80 µg (20 µg of each 
serotype) of tetravalent DNA or tetravalent DENV VLP three times at 3-week intervals. 
DNAs were immunized by intramuscular injection and electroporation, VLPs were 
immunized by regular intramuscular injection with Alum. Serum was collected two 
weeks after the last immunization. DNA_wild type: DENV1-4 prM-E encoding 
plasmids, DNA_F108A: DENV1-4 VLP encoding plasmids, VLP: purified DENV1-4 
VLPs. (A) Serum anti-flavivirus IgG titer was determined by ELISA. Mean log10 
ELISA titers (mean ± SD) are shown. One-way ANOVA followed by Tukey’s multiple 
comparisons test, where *; P < 0.05.  (B) Serum neutralization titers against DENV1-4. 
Each symbol represents the FRNT50 titer from an individual mouse, and the geometric 
mean titers are represented by horizontal bars. One-way ANOVA followed by Tukey’s 
multiple comparisons test, where ***; P < 0.001. **; P < 0.01, *; P < 0.05, ns; not 
significant.  
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Fig. 7. Antibody-dependent enhancement activity of mice serum from tetravalent 
DENV DNA- or VLP-immunized mice.  
DENV1-4 were incubated with serially diluted mice serum or anti-Flavivirus E 
monoclonal antibody and added to the FcγR-expressing BHK cells. After 2 days, 
infected cell numbers were counted. (A-D) Data are shown as fold infection-
enhancement by setting the mean number of infected cells in the absence of serum or 
antibody as 1.0. The mean value of at least 3 negative control wells plus three times 
the standard deviation value (indicated as dotted line) was used as the cut-off value to 
determine ADE activity. 
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1.3 Discussion 
 The global spread and persistence of DENV have made dengue vaccine development 
a pressing matter. In this study, we found an effective strategy to produce DENV VLPs and 
developed a novel tetravalent dengue VLP vaccine which induces strong neutralizing 
responses against all four DENV serotypes. 
 The introduction of an F108A mutation into the E protein increased VLP production 
for all four serotypes of DENV. Amino acid residue F108 is located in the fusion loop of E, 
which is highly conserved among flaviviruses35. During viral infection, the E protein 
undergoes conformational changes that expose the hydrophobic fusion loop on the viral 
surface. The fusion loop is inserted into the host cell membrane and induces a fusion of the 
viral and host cell membranes that results in release of the viral genome into the cytosol22. It 
has been reported that flavivirus VLPs composed of prM-E also undergo a similar process to 
fuse with the cell membranes36. This process may affect the viability of the cells producing 
VLPs and the yield of VLP production. The F108A mutation may prevent VLPs from fusing 
to 293F cells during the production process, thereby leading to the high-level VLP production 
observed. 
 For DENV2 to -4, in addition to the F108A mutation, replacement of the C-terminal 
region with the corresponding region of DENV1 was necessary to achieve efficient VLP 
production (Fig. 2 and 3). The ST/TM region is known to contain a membrane retention 
sequence, which might prevent VLP budding from the plasma membrane28. Replacing aa 297 
to 495 (EDIII and ST/TM) of DENV2 to -4 with those of DENV1 might affect the membrane 
retention sequence in a manner that enhances the secretion of these VLPs. Importantly, based 
on the dengue virus E dimer structure, F108 is in close contact with EDIII37. The contact of 
the F108A mutation and DENV1 EDIII in the DENV2 to -4 VLPs might also affect the 
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structural stability in the context of the dengue virus E dimer structure form, which may 
increase the yield of VLPs. Further studies are needed to support these hypotheses. 
 Although the EDIII region of our DENV2 to -4 VLPs was replaced with DENV1 
EDIII, these VLPs induced serotype-specific NAbs in mice (Fig. 5), suggesting that there are 
neutralizing epitopes located in EDI, EDII, or the EDI/EDII hinge region. These regions have 
been recognized as potent targets of NAbs based on several mapping studies using mouse 
monoclonal antibodies that showed potent neutralizing activities38. Interestingly, recent 
studies showed that EDIII-specific antibodies alone are unlikely to account for the strong 
NAb responses observed in people naturally infected with DENV39-41. In addition, potent 
DENV NAbs that bind to epitopes around EDI/EDII were discovered in DENV-immune 
humans42,43. Our results support the observation that EDI/EDII-targeting antibodies 
contribute to the serotype-specific NAb responses. When mice were immunized with the 
plasmid DNAs encoding our DENV VLPs (prM-E with F108A mutation and C-terminal 
region replacement), we observed higher NAb responses than those of mice immunized with 
DNAs encoding wild-type prM-E (Fig. 6B). This may be reflective of the different VLP 
production levels in vivo. Immunization with DNA induces host cells to produce the 
encoding proteins, resulting in specific immune activation against them44. Indeed, when mice 
were immunized with DENV DNA vaccines, there was a significant correlation between the 
level of in vitro VLP secretion by the DNA vaccine construct and the elicited immune 
responses45. Compared to mice immunized with the DNA vaccines or recombinant E 
proteins, we observed that mice immunized with VLP vaccines induced much higher NAb 
responses (Fig. 5B to D and 6B). VLP-based vaccines have been successful in protecting 
humans from various viruses, including hepatitis B virus and human papillomavirus46. 
Because of their good safety profiles and strong immunogenicity, many other VLP-based 
vaccine candidates, such as those against chikungunya virus (CHIKV), influenza virus, or 
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norovirus, are in clinical trials or under preclinical studies47,48. Although there is no 
commercialized VLP-based vaccine against flavivirus, to date, previous studies have 
demonstrated that coexpression of the prM and E proteins could produce VLPs of West Nile 
virus, St. Louis encephalitis virus, and JEV49,50. Recently, several reports showed that DENV 
VLPs could induce effective NAb responses in mice immunized with a monovalent 
vaccine51,52. However, tetravalent VLP vaccine development has not been very successful. It 
has been reported that a tetravalent DENV VLP vaccine candidate produced in Pichia 
pastoris was immunogenic in mice, but the NAb titers were somewhat low (1:16 to 1:32 by 
the 50% plaque reduction neutralization test [PRNT50] for immunization with 25 µg per 
serotype)53. In our study, tetravalent DENV VLPs induced FRNT50 titers of 1:869 to 1:7,479, 
which suggests that our tetravalent VLP vaccine can achieve more potent NAb responses 
than those obtained with existing candidates. 
 While high levels of NAbs were detected in the VLP-immunized group (Fig. 6), ADE 
activity was absent at the lowest feasible dilution (1:10) (Fig. 7). Strong neutralizing activity 
in a conventional plaque reduction neutralization assay is associated with an absence of ADE 
when tested at the lowest feasible dilution54. It has also been reported that infection 
enhancement activity is absent at low serum dilutions in convalescent-phase patient samples 
that possess high levels of neutralizing activity55. Since immune-enhanced viral replication 
did not occur at the low dilution (1:10) of sera from the VLP-immunized group but occurred 
only at higher dilutions, it is unlikely that immune enhancement would occur under in vivo 
conditions, e.g., with undiluted serum, although further precise preclinical and clinical studies 
regarding ADE effects are needed. 
 Viral interference is a phenomenon observed with tetravalent live attenuated dengue 
vaccines. One or some replication-dominant serotypes interfere with others, resulting in an 
unbalanced immune response15. The tetravalent dengue VLP vaccine is highly unlikely to 
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show viral interference because the VLPs do not replicate. While the live attenuated dengue 
vaccine CYD-TDV requires a 1-year immunization schedule, our DENV VLP vaccine 
immunizations can be completed within about 2 months, which should greatly reduce the risk 
of ADE-mediated severe dengue cases. VLPs can be manufactured efficiently under current 
regulatory standards, and the sequences can be matched easily to those of circulating virus 
strains or emerging new variants if needed. In addition to these advantages, the high-level 
NAb response combined with high levels of VLP production make our tetravalent VLP 
vaccine a promising next-generation dengue vaccine candidate. Furthermore, we 
demonstrated that the F108A mutation and replacement of the C-terminal region of E 
similarly enabled Zika virus (ZIKV) VLP production in 293F cells. This strategy will 
facilitate vaccine development not only against DENV but also against other flaviviruses, 
such as ZIKV or West Nile virus, due to the similarity across flavivirus conserved structures. 
 
1.4 Material and Methods 
Vector construction 
Plasmids encoding structure proteins of DENV were generated by gene synthesis (GeneArt, 
Thermo Fisher Scientific). The signal sequence, prM, and E genes were cloned into pUC119 
based expression vector. The strains used are; DENV1 (Western Pacific strain, Genbank# 
U88535.1), DENV2 (S1 vaccine strain, Genebank# M19197.1 and American strain, 
Genebank# AY744147), DENV3 (Singapore 8120/95 strain, Genebank# AY766104.1) and 
DENV4 (ThD4_0476_97 strain, Genebank# AY618988.1). Mutagenesis was performed by 
QuikChange Lightning Site-Directed Mutagenesis Kit following the manufacturer’s 
instructions (Agilent technologies). Chimeric constructs of DENV2, DENV3, DENV4 E with 
DENV1 E were produced by standard overwrap extension PCR method. Briefly, ss, prM, and 
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aa 1-296 region of E from DENV2, DENV3 or DENV4 were amplified with a universal 
CMV-forward primer and reverse primers that have connective sequences with DENV1 E at 
their 3’ ends. The aa 297-495 region of DENV1 E was amplified using forward primer that 
have same connective sequences at 5’ end and a reverse primer that recognizes poly-A 
region. These PCR products were mixed, amplified, and cloned into NotI and BglII sites of 
pUC59 vector.  
Production and purification of VLPs 
The VLPs were produced in Freestyle 293F cells (Thermo Fisher Scientific). The cells were 
cultured in suspension in serum-free FreeStyle 293 Expression Medium (Thermo Fisher 
Scientific) and transfected with VLP-expressing plasmids by using GeneX Plus transfection 
reagent (ATCC) according to the manufacturer’s instructions. Four days after transfection, 
the cell culture supernatant was harvested, then clarified by centrifugation and filtration with 
0.45 µm polyethersulfone (PES) membrane. The culture supernatant was concentrated, and 
buffer-exchanged to 2.5 mM Sodium-Phosphate Buffer (Teknova) by KrosFlo Research II 
TFF Systems with mPES MidiKros Filter Modules (Spectrum Laboratories). Further 
purification was performed by NGC Quest 10 Chromatography Systems (Bio-Rad) with 
tandemly connected HiTrap Q XL (GE Healthcare Life Sciences) and Foresight CHT Type II 
(Bio-Rad) columns. The VLPs in the flow-through from Q XL column were captured by 
CHT Type II column and eluted with 2.5 to 400 mM sodium phosphate gradient. The eluates 
containing VLPs were concentrated by Amicon Ultra-15 centrifugal filter units (EMD 
Millipore) and filtered with 0.20 µm PES membrane. Total protein concentration of purified 
DENV VLP was measured by Quick Start Bradford Protein Assay (Bio-Rad). Purity of the 
DENV VLP was assessed by SDS-PAGE followed by Coomassie dye-based staining using 
InstantBlue Stain reagent (Expedeon). 
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Western blotting 
VLP-containing culture supernatant was separated by Any kD Mini-PROTEAN TGX Precast 
Protein Gels (Bio-Rad) electrophoresis, and the proteins were transferred onto nitrocellulose 
membranes using Trans-Blot Turbo Transfer System (Bio-Rad). Membranes were blocked 
with 5% skim milk (Labscientific, Inc.) in tris-buffered saline containing 0.05% Tween 20 
(TBS-T) and treated with mouse anti-DENV1-4 E monoclonal antibody (clone 9F10, Santa 
Cruz Biotechnology, 1:500), goat anti-DENV2 E polyclonal antibody (Santa Cruz 
Biotechnology, 1:1000), mouse anti-DENV4 E monoclonal antibody (clone 1H10-6, ATCC, 
20 µg /mL), or anti- Zika rabbit polyclonal antibody (IBT Bioservices, 0.5 µg/mL). 
Membranes were washed in TBS-T, incubated with peroxidase (HRP)-conjugated anti- 
mouse, goat, or rabbit secondary antibody (Santa Cruz Biotechnology, 1:5000), and 
developed using Clarity ECL Western Blot Substrate (Bio-Rad). Imaging and data analysis 
were done by Image Lab software (ver. 5.2.1, Bio-Rad). 
Electron microscopy analysis 
The morphologies of DENV VLPs were analyzed at the Johns Hopkins School of Medicine 
Microscope Facility. Briefly, the purified DENV VLPs were fixed in 4% formaldehyde and 
placed on glow-discharged carbon-coated 200 Mesh copper grids. The grids were then 
stained with 1% phosphotungstic acid and visualized by Philips CM120 Transmission 
Electron Microscopy at 80 kV with AMT XR80 8-megapixel camera. 
Mouse experiment   
Immunization and serum sample preparation were conducted at Bioqual, Inc (Rockville, 
MD). All animal experiments were conducted under Institutional Animal Care and Use 
Committee-approved, and Office of Laboratory Animal Welfare-assured conditions. Female 
BALB/c mice were purchased from Harlan (Frederick, MD). PBS, rE (Prospec, den-021, 
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den-022, den-023, and den-024) and VLP were administered intramuscularly with Alum at 
weeks 0, 3 and 6. DNAs were immunized by intramuscularly injection followed by 
electroporation with a BTX 2 needle array and a BTX model 830 electroporation generator 
(Harvard Instruments) using the following parameters: Six pulses of 100 V with 50 ms 
durations and 200 ms between pulses. Blood samples were taken at weeks 0, 5 and 8. Serum 
was prepared and heat-inactivated by incubating at 60°C for 30 min.  
Anti-Flavivirus IgG ELISA 
Serum anti-flavivirus IgG titer was measured by enzyme-linked immunosorbent assay 
(ELISA). A 96-well ELISA plate was coated with purified JEV (strain: JaOArS982) at 250 
ng/well at 4 °C overnight30. The plate was blocked with Block Ace (DS phama Biomedical) 
for 1 h at room temperature and washed with PBS-0.05% Tween-20 (PBS-T). The test sera 
and standard control were diluted at 1:1,000 and were added to wells, incubated for 1 h at 
37°C, and washed. 1:1,000 diluted HRP conjugated anti-mouse IgG antibody (American 
Qualex) was added and incubated for 1 h at 37°C. Wells were washed and developed with o-
phenylenediamine dihydrochloride (OPD, Sigma) with 0.05M citrate phosphate buffer and 
0.03% H2O2 solution by incubating for 30 min in the dark. Reaction was stopped by adding 
1N HCl and read OD at 492 nm. Titer of sample serum IgG titer was calculated from 
standard curve31. A sample titer ≥ 3,000 were interpreted as anti-flavivirus IgG positive.  
Fifty Percent Focus Reduction Neutralization test (FRNT50) 
Vaccine-immunized mice sera were serially diluted and mixed with 40 to 50 focus-forming 
units of virus (DENV1 99st12A strain -genotype IV, DENV2 oost22A strain -Asian 2, 
DENV3-SLMC50 strain -genotype I, DENV4-SLMC318 strain- genotype I and JEV S-982 
strain-genotype III) and incubated at 37°C for 1 h. Serum-virus mixture was inoculated to 
Vero cell monolayer in 96-well plate and incubated at 37°C for 1 h, then 1.25% 
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methylcellulose 4000 in 2% FCS MEM was added to wells and incubated at 37°C for 3 days 
for DENV and 36 h for JEV. The plates were washed with phosphate-buffered saline (PBS), 
fixed with 4% paraformaldehyde solution for 30 min and washed. Then the cells were 
permeabilized with 1% NP-40 solution for 30 min and washed. The plates were blocked with 
BlockAce for 30 min and treated with 1:1,500 diluted pooled human sera having high anti-
flavivirus IgG titers31 for 1 h at 37°C. Subsequently, HRP-conjugated goat anti-human IgG 
(American Qualex, 1:1,500) was added and incubated at 37°C for 1 h. 0.5 mg/ml of 3,3'-
diaminobenzidine tetrahydrochloride (Wako) with 0.03% of H2O2 solution was added and 
incubated for 10 min for staining. After washing and air drying, the number of foci per well 
were counted using a biological microscope. The reciprocal of the endpoint serum dilution 
that provided 50% or greater reduction in the mean number of foci relative to the control 
wells that contained no serum was considered to be the FRNT50 titer. 
Antibody-dependent dengue virus infection enhancement assay 
FcγR-expressing BHK cell lines34 were seeded in to a 96 well plate and cultured in EMEM 
supplemented with 10 % heat-inactivated FBS and G418. Vaccine immunized mouse serum 
or mouse anti-Flavivirus E monoclonal antibody 4G2 were serially diluted from 1:10 to 
1:10,000 with 10% FBS /EMEM, and mixed with 30-50 focus-forming units of virus (same 
DENV strains as those used in FRNT assay) and incubated at 37°C for 1 h. Virus-immune 
complex were added to each well of the cells, and cultured for 48 h. The cells were washed 
with PBS once, dried by air, and fixed with ice-cold methanol-acetone (1:1). After the plates 
are air-dried, the wells were blocked with 1% horse serum in PBS for 10 min, and washed 
with PBS for three times. The plate was then treated with anti-flavivirus antibody (mAb 4G2 
at a dilution of 1:1000) at 37°C for 30 min, biotin conjugated anti-mouse IgG antibody 
(Vector Laboratories, 1:500) at room temperature for 30 min, and ABC (Vector Laboratories) 
solution at room temperature for 30 min. The plate was washed with PBS three times after 
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each incubation step. VIP solution (Vector Laboratories) was added and incubated at room 
temperature for few minutes until color was developed. The plate was washed with PBS 
once, infected cells were quantitated (Keyence BZ-X710 microscope). Fold-enhancement 
values were calculated using the following formula: (mean infected cells count using FcγR-
expressing BHK cells with the addition of mouse serum sample)/ (mean plaque count using 
FcγR-expressing BHK cells in the absence of test sample). Infection enhancement (measured 
as ADE activity) was tested using serum samples that was diluted from 1:10 to 1:10,000. The 
fold enhancement values were determined as follows: (the mean number of DENV infected-
cells in wells treated with serum samples)/ (the mean number of plaques in wells with 
monolayers incubated in the absence of test samples). The mean value of at least 3 negative 
control wells plus three times the standard deviation (SD) value was used as the cut-off value 
to determine which samples had ADE activity56. 
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Chapter 2:  
Development of novel vaccine platform utilizing 
alphavirus VLP and its application to malaria vaccine 
 
2.1 Introduction 
 VLP technology is a very powerful method for developing vaccines1,3,57. Through 
genetic fusion or chemical conjugation, VLPs are attractive carrier proteins of foreign 
antigens since they can efficiently display them within a host immune system58-60. An 
important advantage of VLP-based vaccine platforms is that VLPs can present antigens in a 
dense, repetitive manner, thus effectively enabling the cross-linking of B cell receptors 
(BCRs)61. Multivalent antigens bound to BCRs show more efficient processing and 
presentation than monovalent antigens62. Cross-linking of BCRs by multivalent antigens 
leads a conformational change in BCRs and induces signaling-active BCR micro-cluster 
formation, leading to robust B cell activation and signaling63. Therefore, VLP-based 
approaches offer great potential for developing effective vaccines against many pathogens, 
including antigens known to be weakly immunogenic. 
 Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that causes chikungunya 
fever. The genome of the CHIKV is composed of a positive single-stranded RNA encoding 
four nonstructural (nsP1 to nsP4) and five structural (C, E3, E2, 6K, and E1) proteins. The 
five structural proteins are translated as a single polyprotein, from which the capsid (C) 
protein is cleaved off by capsid auto-proteinase. The envelope polyprotein precursor (E3-E2-
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6K-E1) is translocated to the endoplasmic reticulum (ER) and further processed by host 
signalases, resulting in E1, 6K, and p62 (or the E3E2 precursor polyprotein). E1 and p62 are 
subsequently assembled as heterodimers in the ER and processed through the Golgi and 
trans-Golgi networks, where p62 undergoes a furin dependent maturation cleavage. The 
resulting mature CHIKV virion contains 240 heterodimeric spikes of E2/E1 on its 
surface64,65. It is the expression of the structural proteins that gives rise to a chikungunya VLP 
(CHIK VLP), which has an icosahedral structure comprised of 240 copies of envelopes per 
particle arranged in a symmetric, repetitive array (triangulation number [T] = 4). CHIK 
VLPs, per se, have been shown to be a promising vaccine candidate against CHIKV: 
immunization with CHIK VLPs themselves induced a strong neutralizing antibody response 
against CHIKV in mice and monkeys and prevented viremia in monkeys after subsequent 
challenge with CHIKV66. Furthermore, a phase I clinical trial demonstrated that CHIK VLP 
vaccine was safe and highly immunogenic67. 
 In this study, by leveraging the solid safety profile and potent immunogenicity of 
CHIK VLPs, we created a novel vaccine platform derived from CHIK VLPs whereby foreign 
antigens were engineered for insertion into two positions within the surface-loop domains of 
the CHIKV envelope, resulting in 240 or 480 copies of antigen displayed on the CHIK VLP 
surface. This repetitive, highly symmetric array of antigens greatly enhances immune 
responses per the explanation on BCR multimeric crosslinking and downstream activation 
given above. Here, we describe the characteristics of our novel VLP vaccine platform and 
demonstrate its efficacy and applicability in the context of the malaria CSP antigen, a major 
surface antigen expressed on the surface of malaria sporozoites and involved in the initial 
infective stage by malaria parasites in humans68. The central region of the P. falciparum 
malaria strain’s CSP contains multiple tetrapeptide (Asn-Ala-Asn-Pro [NANP]) repeats. It 
has been reported that the NANP repeats are a B cell dominant epitope and that anti-NANP 
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antibodies play an important role in protection from malarial infection69. By incorporating the 
CSP repeat region as epitopes into our VLP platform, our vaccine induced high titers of anti-
CSP antibodies in mice and monkeys and conferred protection against malarial infection in 
preclinical studies. 
 
2.2 Results 
2.2.1 Development and characterization of CHIK VLP-based vaccine platform 
 The expression of CHIKV structural proteins produces CHIK VLP in mammalian 
cells66. First, we prepared an expression vector encoding CHIKV structural proteins (C-E3-
E2-6K-E1) with a short linker introduced in E2, which will produce a VLP (here called αVLP) similar to the wild-type CHIK VLP (Fig. 8A, αVLP). During viral replication, E1 and 
p62 (or E3E2) are assembled as p62/E1 heterodimers and form 80 trimeric glycoprotein 
spikes. Eventually, p62 is cleaved into E3 and E2 by furin to produce the mature E2/E1 
dimer, and E2 binds to receptors on the surface of a host cell, playing an important role in 
virus infection64,65,70. It has been reported that the p62/E1 heterodimer is more acid resistant 
than the E2/E1 heterodimer and that the retention of E3 on the CHIK VLP enhances the 
stability of VLPs23. We hypothesized that the E3 retained on CHIK VLP inhibits VLP 
binding and fusion to host cells and enhances the immune stimulatory activity of the vaccine 
platform. To test this hypothesis, we also created an expression vector for E3E2 cleavage-
impaired αVLP (E3αVLP, E3 retained on αVLP) by mutating the furin recognition site (Fig. 
8A, E3αVLP). 
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 When transfected into 293F cells, the VLPs are secreted into the culture supernatant. 
We purified the VLPs and confirmed the protein expression using SDS-PAGE, followed by 
Coomassie blue staining. The results indicated the presence of capsid (30 kDa), E1 and E2  
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(both around 50 kDa) for αVLP, or E1 (50 kDa) and p62 (62 kDa) for E3αVLP (Fig. 8B). 
Next, we investigated the ability of these VLPs to enter cultured cells. Epithelium derived 
cell lines, including human embryonic kidney 293 cells, are highly susceptible to CHIKV71. 
αVLP- or E3αVLP-containing culture supernatant was added to the culture medium of 
adherent 293 cells, followed by incubation for 72 h. The culture medium was then clarified 
and analyzed for the levels of remaining VLP. Only E3αVLP was detected in the culture 
medium (Fig. 8C), suggesting that the retained E3 had prevented VLP entry into the cells. 
The entry of VLPs was further examined by using pseudotyped lentiviral vectors 
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Fig. 8. Development and characterization of αVLP vaccine platform.  
(A) Schematic representation of the CHIKV genome, and αVLP- or E3αVLP-
expression vectors. Black solid arrowhead; capsid autoproteinase cleavage site, red  
solid arrowhead; furin recognition sequence, open arrowheads; signal peptidase 
cleavage sites. (B) Purified αVLP and E3αVLP were separated by SDS-PAGE and 
visualized by Coomassie Blue staining. (C) αVLP or E3αVLP was added to the culture 
medium of adherent 293 cells and incubated for 72 hr. The VLPs in the culture 
supernatant were detected by western blotting using mouse anti-CHIKV antiserum. (D) 
Infectivity of the indicated pseudotyped lentiviral vectors in CHIKV-permissive cell 
lines, 293 and NIH3T3 cells. After incubation with pseudotyped lentiviral vectors for 
72 hr, GFP expression was assessed by flow cytometry.  
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incorporating E2/E1 or p62/E1 glycoproteins. The pseudotyped lentiviral vector 
incorporating E2/E1 from αVLP showed infection of 293 cells and mouse fibroblast NIH 3T3 
cells, cell lines that are permissive to CHIKV replication. In contrast, the pseudotyped vector 
incorporating p62/E1 from E3αVLP did not show infection of the cells (Fig. 8D), supporting 
our hypothesis that E3 prevents VLP entry into host cell. 
 In vivo stability and distribution of αVLP and E3αVLP. To examine these VLP’s 
stability and distribution in vivo, purified αVLP or E3αVLP was administered intravenously 
to mice, and the presence of VLPs in the spleen was assessed through staining with CHIKV-
specific antibody (Fig. 9A). Both αVLP and E3αVLP (green) were trapped in marginal zone 
macrophages after 30 min (MARCO+, red). At day 1, αVLP was sporadically distributed, 
whereas E3αVLP preferentially accumulated in the B cell areas of the white pulp (inside 
CD169+, blue). At day 14, αVLP was almost undetectable; however, a significant amount of 
E3αVLP was retained in the germinal center (GC; GL7+, red). Quantitative image analysis 
over this time course further supported the long-lasting feature of E3αVLP in vivo (Fig. 9B). 
These results strongly suggest that the retained E3 enhanced VLP tissue retention in the GCs 
after administration compared to αVLP. 
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Fig. 9. In vivo stability and distribution of αVLP and E3αVLP. 
(A) Splenic sections were stained for αVLP or E3αVLP (green), CD169 (blue), MARCO 
(red), and GL7 (red) over a 14-day time course. At each time point, the left panel shows 
αVLP and the right panels shows E3αVLP.  Representative images from three 
independent experiments are shown. (B) Quantitative analysis of VLP staining was 
performed on pixel basis with 5 different spleen areas of the longitudinal section and 
normalized for αVLP or E3αVLP at day 1 staining as 1.0. Data are presented as mean ± 
SEM. Significance was evaluated for αVLP vs E3αVLP at the corresponding days by 
Mann Whitney test. *P < 0.05. **P < 0.01. 
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2.2.2 Cryo-EM structure of E3αVLP 
 The structure of was closely investigated by the cryo- EM. The cryo-EM density map 
of E3aVLPs attained 6.7 Å resolution (Fig. 10A). The VLP had a diameter of 660 Å and, like 
the mature virus, has T=4 icosahedral symmetry. Central cross-sections of the reconstruction 
showed that E3aVLP had a nucleocapsid, enveloped by a plasma membrane and an 
outermost layer of glycoproteins with a well-ordered icosahedral nucleocapsid within the 
membrane envelope (Fig. 10B). Same as mature CHIKV virions or αVLPs, E3αVLPs had 
spike-like features (Fig. 11A) on their surface. Intraspike contacts were formed between the 
three E2 molecules that form a spike. The glycoprotein E1 wrapped around E2 and 
contributes to inter-spike interactions.  
 Furthermore, E3 was located at the periphery of the E2 molecules (Fig. 11A). The 
trimeric immature spikes, although organized with T=4 quasi-symmetry, were similar to 
mature CHIKV spikes, but were less compact with a hole along their three-fold axes, 
resulting in a bigger spike radius. The spikes are more densely packed on the surface of 
E3aVLP resulting in smaller holes along the icosahedral two-fold (i2) and icosahedral five-
fold (i5) symmetry axes, and smaller separation between the spikes, in comparison with the 
mature CHIKV (Fig. 11B). Thus, the spikes undergo a structural rearrangement during 
maturation. 
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Fig. 10. Cryo-EM reconstruction of “immature” CHIK virus-like particle.  
(A) 3D cryo-EM map of E3αVLP viewed down an icosahedral twofold axis. An 
icosahedral asymmetric unit is marked by a black triangle. Icosahedral symmetry 
elements are shown in the black filled pentagon, triangles and ellipse. Four unique 
subunits in an asymmetric unit were shown in white numbers. (B) Internal capsid 
protein shell of the E3αVLP. (C) Central cross-sections of the E3αVLP viewed down 
an icosahedral two-fold axis. Components of the virus are shown in different colors. 
(D) Enlarged view of the region outlined by the black rectangle in (C). Fitting of an 
E1-p62-C structure in the cryo-EM map of E3αVLP is shown. 
 39 
 
 
  
Fig. 11. Structural characteristics of the “immature” CHIKV.  
(A) A trimeric spike of the E3αVLP. The E2 molecules (red) form interactions within a 
spike while the E1 molecules (yellow) wrap around E2 molecules and form 
interactions between spikes. The E3 molecules (green) are located at the periphery of 
E2 molecules. (B) Central cross-section of the E3αVLP and αVLP. The icosahedral 
symmetry axes are indicated in white arrows. Components of the viruses are shown in 
different colors.  
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2.2.3 Characterization of αVLPs inserted with malaria antigen 
 To test αVLP’s capacity to accommodate foreign antigens, we identified two potential 
antigen insertion sites located in the surface loop region of CHIKV envelope based on the 
crystal structure of CHIKV65. A foreign antigen can be inserted within E2 of αVLP (Fig. 
12A, insertion site 1) or into the mutated furin cleavage site of E3αVLP (Fig. 12A, insertion 
site 2). When transfected into 293F cells, the inserted antigen and the viral envelope are 
expressed as a fusion protein and self-assemble into VLPs. As described in the introduction, 
CHIK VLP is comprised of 240 copies of E2/E1 heterodimeric envelopes per particle. 
Therefore, 240 copies of foreign antigen will be displayed on the αVLP surface in a 
symmetrical manner, which is known to enhance B cell signaling and induce high antibody 
titers1,72. By utilizing this platform, we developed new malaria vaccine candidates, which 
display the central NANP repeat region of circumsporozoite protein (CSP) of the P. 
falciparum as the epitope on the VLPs. CSP is the major surface antigen displayed during the 
infective stage of malaria and has been recognized as a likely target for malaria vaccine 
development69,73. The repeat region is highly conserved among different strains of P. 
falciparum, and it is considered an immunodominant B cell epitope74. We inserted five 
NANP repeats into the cloning sites of αVLP (αVLP-NANP) and E3αVLP (E3αVLP-
NANP). We also constructed Dual-NANP, which has the NANP repeat epitope in both 
insertion sites (Fig. 12A, Dual), thus displaying 480 copies of five NANP repeats per VLP. 
 The NANP-inserted VLP expression was determined by Western blotting directly in 
the culture supernatants using anti-CHIKV antiserum (Fig. 12B). Mice were injected with the 
VLPs, and serum anti-NANP antibody titer was assessed by ELISA. Dual-NANP elicited the 
highest antibody titer among the three VLPs, and E3αVLP-NANP induced a significantly 
higher titer compared to αVLP-NANP (Fig. 12C). The endpoint titers (determined as 
described in Materials and Methods) were as follows:  
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Fig. 12. Characterization of αVLPs inserted with malaria antigen.  
(A) Epitope insertion sites of αVLP and E3αVLP envelope. Arrows insertion positions. 
(B) Western blotting analysis of VLPs inserted with NP(NANP)5NA epitope. 
Expression vectors were transfected into 293F cells and culture supernatant were tested 
for VLP expression on day 4. A representative image from at least 3 replicates is shown. 
(C) Immunogenicity in mice. BALB/c mice (N=4) were immunized intramuscularly 
twice at 3-week interval with 10 µg of the indicated VLPs with NP(NANP)5NA epitope, 
and serum anti-NANP antibody titer was determined by ELISA on day 31. Data are 
shown as the mean endpoint titer ± SEM. One-way ANOVA followed by Dunnett’s 
multiple comparisons test, where *P < 0.05; **P < 0.01.  
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αVLP-NANP, 418; E3αVLP-NANP, 8,044; and Dual-NANP, 28,264. Structure and 
immunogenicity of VLPM01, an αVLP-based malaria vaccine candidate. Next, we optimized 
the length of the NANP repeat epitope. We evaluated the immunogenicity of the VLPs 
inserted with different numbers of NANP repeats and found that the Dual-NANP inserted 
with 13 NANP repeats (here called VLPM01) induced high titer anti-NANP antibodies 
without sacrificing VLP yield. Examination of the purified αVLP and VLPM01 by EM 
demonstrated that the VLPs have similar morphology as the native virus (Fig. 13A, top and 
middle). Three-dimensional cryo-EM reconstruction of VLPM01 showed that it has a 
diameter of 67 nm and a T= 4 quasi-icosahedral symmetry, which is similar to the previously 
described CHIK VLP structure and other alphaviruses (Fig.13B, left). A 3D cryo-EM 
reconstructed map of VLPM01 complexed with the fragment antigen-binding (Fab) region of 
anti-NANP repeat monoclonal antibody (clone DG2) showed that NANP epitopes in both 
insertion sites were exposed on the surface of the VLPM01 particles and were accessible to 
the binding of Fab fragments (Fig. 13B, right). The EM image of VLPM01-DG2 complex is 
shown in Fig.13A (bottom). 
 We also tested the immunogenicity of VLPM01 in mice and compared the antibody 
response with other nanoparticles displaying NANP epitopes. We have chosen two self-
assembling protein nanoparticle platforms, hepatitis B virus core protein (HBc) and ferritin. 
HBc self-assembles into VLP which possesses strong immunogenic properties, and HBc VLP 
has been used extensively to present epitopes in the design of potential vaccines75. Among 
those, HBc VLP displaying the central repeat region of P. falciparum CSP 
[NANPNVDP(NANP)3] has been reported as malaria vaccine candidate ICC-1132. We 
created HBc VLP with the CSP repeat epitope inserted and produced it in Escherichia coli as 
previously described76. Ferritin is an immunogenic VLP-like nanoparticle, and it has been 
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demonstrated that genetically engineered ferritin nanoparticles can present a multivalent 
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Fig. 13. Characterization of αVLP-based malaria vaccine candidate, VLPM01.  
(A) Representative EM images of control αVLP, VLPM01, and VLPM01 complexed 
with the DG2 Fab fragments. (B) Cryo-EM reconstructions of VLPM01. Upper-left, 
3D cryo-EM map of VLPM01, viewed down an icosahedral twofold axis. The black 
triangle marks the boundary of an icosahedral asymmetric unit. The numbers in black 
show the location of the icosahedral two-, three- and fivefold axes around the 
asymmetric unit. Bottom-left, a closer view of the icosahedral three-fold trimeric spike 
in VLPM01 fitted with the crystal structure of CHIK p62-E1 (PDBID:3N40). Gold 
arrows are pointing to the insertion site at E2 and blue arrows are pointing to the 
insertion site at E3. Upper-right, 3D cryo-EM map of VLPM01 complexed with the 
DG2 Fab fragments. Bottom-right, a trimeric spike on the icosahedral three-fold axis 
of VLPM01 complexed with Fab fragments of DG2. Gold arrows are pointing to the 
DG2 Fabs density bound on the insertion site at E2. Blue arrows are pointing to the 
DG2 Fabs density bound on the insertion site at E3. 
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of various virus antigens2,77. We inserted the same number of NANP repeat as in VLPM01 
into ferritin and produced it in 293F cells. EM confirmed that HBc-NANP and ferritin-NANP 
formed particles 31 to 40 nm and 12 to 16 nm in diameter, respectively (Fig. 14A). Mice 
were immunized with control VLP (αVLP without NANP epitope), VLPM01, HBc-NANP, 
or ferritin-NANP, and the anti-NANP antibody titer was measured. The average endpoint 
titer (final dilution) of VLPM01 -immunized mice was 563,489, which was significantly 
higher than the titers for the other groups (Fig. 14B). The endpoint titers were as follows: 
HBc-NANP, 2,017; ferritin- NANP, 12,809; and control VLP, 1,157. These results suggest 
that the αVLP vaccine platform is very efficient at inducing immune responses against the 
displayed epitope. 
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Fig. 14. Comparison the immunogenicity of αVLP-based malaria vaccine 
candidate, VLPM01 with other vaccine platforms.  
(A) Representative transmission electron microscopic images of HBc-NANP and 
Ferritin-NANP. (B) BALB/c mice (N=4) were intramuscularly injected with 10 µg of 
control αVLP (no insert), VLPM01 (inserted with NP(NANP)13NA), HBc-NANP 
(inserted with NANPNVDP(NANP)3) or Ferritin-NANP (inserted with 
NP(NANP)13NA) and anti-NANP antibody titer was determined by ELISA on day 14. 
Data are shown as the mean endpoint titer ± SEM. One-way ANOVA followed by 
Dunnett’s multiple comparisons test, where ***P < 0.001. 
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2.2.3 Efficacy of αVLP-based vaccine against malaria challenge in mouse 
model 
 The immunogenicity of VLPM01 was further tested with three different doses, 
together with alum adjuvant, in mice. The lowest dose of 0.15 µg was clearly immunogenic, 
and alum enhanced the anti-NANP antibody response compared to the use of VLPM01 alone 
(Fig. 15A). Next, we immunized rhesus macaques with 45 µg of VLPM01 with alum. A 
single immunization of VLPM01 stimulated the production of anti-NANP antibodies, and the 
immune response was enhanced by booster immunizations. The serum anti-NANP titer was 
maintained at high levels 6 months after the third immunization (Fig. 15B). The estimated 
anti-NANP antibody concentrations in the immunized monkey sera were 258 µg/ml 
(geometric mean anti-NANP antibody titer of 79,503 defined as the dilution factor to give an 
optical density [OD] of 1.0) and 231 µg/ml (70,655 defined as the dilution factor to give an 
OD of 1.0) after the second and third immunizations (measured at weeks 6 and 10), 
respectively.  
 To further examine the applicability of the αVLP vaccine platform, we assessed the 
protective efficacy of αVLP-based CSP vaccines using two malaria challenge models. First, 
we intravenously injected mice with the serum from an unimmunized or a VLPM01-
immunized monkey and challenged the animals with murine malaria P. berghei sporozoites 
expressing a functional P. falciparum CSP (P. berghei /P. falciparum full sporozoites)78. 
Liver parasite burdens were assessed 40 h post challenge by quantitative PCR (qPCR) for P. 
berghei-specific 18S rRNA. The mice administered VLPM01-immunized monkey serum 
showed a >99.5% reduction in liver parasite burden (Fig.15C), suggesting that the humoral 
responses induced by VLPM01 are sufficiently potent to prevent the liver-stage development 
of P. falciparum. Next, we prepared Dual-PyCSP, an αVLP with 14 QGPGAP repeat 
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sequences from CSP of rodent malaria parasite P. yoelii inserted. Mice were immunized with 
two doses of control αVLP or Dual-PyCSP, and anti-PyCSP repeat antibody production was 
confirmed by ELISA (Fig. 15D). The mice were challenged intravenously with infectious P. 
yoelii sporozoites, and parasitemia was determined by a Giemsa-stained thin blood smear 
procedure on day 14 post challenge. In the control αVLP-immunized group, 9 of 10 mice 
were infected with malaria parasites. In contrast, only one mouse was infected in the Dual-
PyCSP-immunized group, yielding 89% vaccine efficacy (Fig. 15E). These results were also 
confirmed by reverse transcription-PCR analysis of P. yoelii-specific 18S rRNA at 14 days 
post challenge in livers (data not shown). Taken together, the humoral immune responses 
induced by our αVLP-based vaccines confer significant protection against malaria infection. 
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  Fig. 15. αVLP-based vaccine protected mice from malaria challenge. 
(A) BALB/c mice (N=5) were immunized intramuscularly with the indicated doses of 
VLPM01 with or without Alum three times at 3-week intervals. Two weeks after the last 
immunization, anti-NANP antibody titer was determined by ELISA. Data are shown as the 
mean endpoint titer ± SEM. Student’s t-test, where ***P < 0.001. (B) Rhesus macaques 
(N=4) were immunized intramuscularly with 45 µg of VLPM01 with Alum three times at 
4-week intervals. Serum anti-NANP antibody titer were determined by ELISA. Data are 
shown as the mean endpoint titer ± SEM. (C) B6 mice (N=5) were injected intravenously 
with 450 µl of control or VLPM01-immunized monkey sera, then challenged intravenously 
with Pb/Pf full CSP sporozoites. Liver parasite burdens were assessed 40 hr post-challenge 
by qPCR for P. berghei-specific 18S rRNA. Results are shown as percent inhibition 
compared to naïve, infected mice. (D) P. yoelii challenge experiment. BALB/c mice (N=10) 
were immunized intramuscularly with 20 µg of control αVLP (no insert) or Dual-PyCSP 
(inserted with (QGPGAP)14) with Alum twice at 3-week interval. Anti-PyCSP repeat 
antibody titer was measured 12 days following the second immunization. Data are shown 
as the mean endpoint titer ± SEM. Student’s t-test, where ***P < 0.001. (E) Malaria 
infection was determined by a Giemsa-stained thin blood smear procedure 14 days after the 
challenge.  
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2.3 Discussion 
  In this study, we created and characterized a novel vaccine platform based on CHIK 
VLP. Our data demonstrate that our αVLP vaccine platform can elicit high titer antibody 
responses against the inserted foreign antigen in mice and monkeys. 
 We developed wild-type αVLP and E3E2 cleavage-impaired E3αVLP and compared 
their characteristics in vitro and in vivo. Notably, E3αVLP which retains E3 on the particle 
was detectable longer in vivo and preferentially associated with GCs in the lymphoid organs. 
It is possible that the retained E3 stabilizes the VLP, enabling E3αVLP to remain in contact 
with B cells in GCs longer than αVLP (Fig. 9B). GCs are sites where high-affinity memory B 
cells are generated79, and the sustained presence of E3αVLP can effectively promote immune 
responses. This is supported by evidence of E3αVLP-NANP inducing a significantly higher 
antibody titer against the inserted antigen compared to the furin-sensitive, wild-type αVLP-
NANP (Fig. 12C). The density of antigens is important for B cell activation. Like native 
CHIKV, αVLP’s quasi-crystalline surface with repetitive antigen array can be easily 
recognized by B cells. As shown in Fig. 13B, 480 copies of inserted antigens are displayed on 
the particle surface and bind to Fab. The distances between Fabs on the neighboring spikes 
are 10 to 15 nm, which is within the wingspan of typical IgG molecules (10 to 20 nm), 
suggesting that αVLP presents epitopes at optimal distances to facilitate BCR activation by 
bivalent engagement. 
 To assess the utility of our αVLP vaccine platform, we focused on the NANP repeat 
antigenic region of the CSP surface protein of P. falciparum. CSP of P. falciparum has been 
extensively studied as a promising malaria vaccine target. It has been reported that soluble 
recombinant P. falciparum CSP was highly immunogenic, and the immunogenicity was 
further enhanced by presenting CSP antigen on nanoparticles and VLPs78,80. αVLP-based 
 50 
malaria vaccine, VLPM01, successfully elicited high levels of anti-CSP NANP repeat 
antibody. The humoral immune responses induced by VLPM01 conferred protection against 
malaria infection. The immune response was maintained 6 months after the last booster 
immunization in monkeys (Fig. 15B).  
 A caveat to the use of VLPs as a vaccine platform is the potential for reduced 
immunogenicity stemming from any preexisting immunity against the derivative virus or 
other cross-reactive viruses. Although this was the case for some viral vaccine vectors, it has 
also been reported that antibody responses against herpes simplex virus- or poliovirus-
vectored antigens were not affected by prior immunities81. The isolation and characterization 
of human monoclonal antibodies from CHIKV infected and recovered individuals82 and the 
screening of a panel of mouse and human monoclonal antibodies against CHIKV83 revealed 
that the dominant neutralizing epitopes are located in E2 protein of CHIKV. In VLPM01, 
those epitopes are partially masked by the retained E3 or disrupted by the inserted NANP 
epitopes. Therefore, we expect that preexisting anti-CHIKV neutralizing antibodies induced 
by natural CHIKV infection may have minimal impact on VLPM01’s vaccine 
immunogenicity. Although more studies are needed on the effects of preexisting immunity, 
our preclinical data convincingly demonstrate that our VLP vaccine bears unique and 
promising advantages as a new generation vaccine platform. First, by engineering two 
insertion sites, αVLP can display two different antigens of choice at 240 dense copies each. 
Second, our VLP can display relatively large antigens depending on their structure. 
Combined with the good safety profile and generally robust immunogenicity induced by 
VLPs, αVLP technology holds the promise of serving as a powerful template for the 
development of next-generation vaccines against many other pathogens and diseases. 
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2.4 Material and Methods 
Vector construction 
A gene coding for CHIKV strain 37997 structural proteins (C-E3-E2-6K-E1) was synthesized 
by Blue Heron and cloned into pUC119-derived vector under the control of human 
cytomegalovirus early-immediate promoter. The plasmid encoding VLP was created by 
inserting BspEI and BamHI restriction sites as a Ser-Gly-Gly-Gly-Gly-Ser linker between 
amino acids (aa) 206 and 207 in the E2 domain. The plasmid encoding E3VLP was prepared 
by replacing the furin cleavage site (E3 aa 61 to 64) with the Ser-Gly-Gly-Gly-Gly-Ser 
linker. SacII restriction site was introduced without changing the amino acid sequence to the 
E2 domain (aa 197 to 198) to create dual-epitope constructs. VLP-NANP and E3VLP-NANP 
were prepared by inserting the GNP(NANP)5NAG sequence into the BspEI/BamHI cloning 
sites of VLP or E3VLP, respectively. Dual-NANP was prepared by replacing NotI/SacII 
region of VLP-NANP with NotI/SacII fragment of E3VLP-NANP. The epitopes for other 
constructs used were as follows: VLPM01, GNP(NANP)13NAG; and Dual-PyCSP, 
G(QGPGAP)14G. The gene encoding ferritin-NANP was created as follows and cloned into 
pUC59. The leader sequence of human IL-2 (aa 1 to 19), followed by the Ser-Gly-Gly-Gly-
Gly-Ser linker and Helicobacter pylori non-heme-iron-containing ferritin (aa 5 to 167; 
GenBank WP_000949190) with a point mutation (N19Q)77, was synthesized by GeneArt 
(Thermo Fisher Scientific). The NANP epitope, GNP(NANP)13NAG, was inserted into the 
BspEI/BamHI cloning sites within the linker. HBc-NANP was created based on the 
previously reported malaria vaccine candidate76. The NANP epitope, NANPNVDP(NANP)3 
modified by the addition of 5= BspEI and 3= BamHI cloning sites, was inserted between aa 
78 and 79 of the truncated HBc (aa 1 to 149). The gene encoding HBc-NANP was 
synthesized by GeneArt and cloned into pET-30a vector (EMD Millipore).  
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Cell lines 
FreeStyle 293F cells were purchased from Thermo Fisher Scientific and cultured in 
suspension in serum-free FreeStyle 293 expression medium at 37°C in the presence of 8% 
CO2. The cells were authenticated by short tandem repeat profiling and confirmed to be free 
of mycoplasma contamination by using a LookOut mycoplasma PCR detection kit (Sigma-
Aldrich). 293T/17, 293, and NIH 3T3 cells were obtained from the American Type Culture 
Collection (ATCC). 293 cells (293F cells in CD293) were obtained from Thermo Fisher 
Scientific. The cells were cultured in Dulbecco modified Eagle medium (Sigma-Aldrich) 
containing 10% fetal bovine serum and penicillin- streptomycin solution (Thermo Fisher 
Scientific) at 37°C in the presence of 5% CO2. Antibodies against CHIKV and CSP-NANP. 
Mouse and rabbit anti-CHIKV antisera were obtained from animals immunized with 20 µg of 
CHIK VLP three times at 3-week intervals. Anti-NANP mouse monoclonal antibody (clone 
DG2) was generated from a female BALB/c mouse immunized with Dual-NANP with Ribi 
adjuvant (Sigma-Aldrich). At 4 days after the last inoculation, the spleen was aseptically 
removed for hybridoma preparation according to standard procedures84. Hybridomas 
producing antibodies that recognize NANP peptides but do not react with CHIK VLP were 
screened by ELISA and further cloned. The supernatants of hybridoma cultures were 
collected, clarified by centrifugation, and filtered through a 0.45 µm pore size membrane 
filter. The antibody was purified by using an rProtein A/Protein G GraviTrap kit (GE 
Healthcare Life Sciences) according to the manufacturer’s instructions. 
Production and purification of VLPs 
The VLPs except for HBc-NANP were produced in FreeStyle 293F cells. The cells were 
transfected with VLP-expressing plasmids by using GeneX Plus transfection reagent (ATCC) 
according to the manufacturer’s instructions. At 4 days after transfection, the cell culture 
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supernatant was harvested and clarified by centrifugation and filtration with 0.45- m-pore 
size PES membrane. The VLPs secreted in the culture supernatant were collected by using 
OptiPrep density gradient medium (Sigma-Aldrich) as described previously66 and further 
purified by using a HiPrep 16/60 Sephacryl S-500 HR column (GE Healthcare Life 
Sciences). The eluates containing purified VLPs were concentrated by Amicon Ultra-15 
centrifugal filter units (EMD Millipore) and filtered with a 0.20 µm pore size PES membrane. 
HBc-NANP VLPs were expressed in E. coli and purified by ammonium sulfate precipitation 
and column chromatography. The E. coli strain, DH5, was transformed with pET-HBc-
NANP plasmid, and a single colony was cultured. VLP expression was induced by adding 0.1 
mM IPTG (isopropyl- -D-thiogalactopyranoside), and the cells were harvested, resuspended 
in TSE buffer (20 mM Tris-HCl [pH 7.9], 150 mM NaCl, 1 mM EDTA), and sonicated. 
Soluble lysate was collected by centrifugation and, after ammonium sulfate precipitation, the 
VLPs were purified using a combination of Superdex 200 and MonoQ columns (GE 
Healthcare Life Sciences). The eluates containing purified VLPs were pooled, concentrated, 
and dialyzed in a buffer containing 50 mM Tris-HCl (pH 7.4), 50 mM NaCl, and 1 mM 
EDTA. The purified VLPs were separated by SDS-PAGE and stained with InstantBlue 
Coomassie protein stain (Expedeon). VLP entry into 293 cells. 293 cells were maintained as 
adherent monolayer cultures, plated on a 12-well culture plate at 105 cells/well, and cultured 
overnight. The VLP-containing culture supernatants were added to the well and, after 72 h, 
the conditioned medium was collected and analyzed for the remaining VLPs by Western 
blotting with mouse anti-CHIKV antiserum.  
Western blotting 
VLP-containing culture supernatant was separated by SDS-PAGE, and the electrophoresed 
proteins were transferred onto nitrocellulose membranes and blotted with mouse anti-CHIKV 
antiserum. After incubation with HRP-conjugated goat anti-mouse IgG (Santa Cruz 
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Biotechnology), membranes were developed using Clarity ECL Western blot substrate (Bio-
Rad Laboratories). 
 Production of pseudotyped lentiviral vectors and cell entry analysis. We created 
plasmids expressing glycoproteins E1/E2 and p62/E1 from VLP and E3VLP expression 
vectors. Other lentiviral plasmids were purchased from Cell Biolabs. 293T/17 cells were 
seeded onto a 10-cm dish at a density of 2x 106 cells one day before transfection. The cells 
were transfected with 4 µg of glycoprotein expression plasmid, 12 µg of a transducing vector 
encoding a GFP reporter gene (pLenti-GFP), 4 µg of a packaging plasmid that expresses all 
HIV-1 structural proteins except Env and Rev (pCgpV), and 4 µg of a Rev expression vector 
(pRSV-REV) using Lipofectamine 2000 reagent (Thermo Fisher Scientific). Empty vector 
(pUC19) served as negative control. Packaged lentivirus-containing supernatant was 
collected by centrifugation and filtered through a 0.22 µm membrane. 293 cells and NIH 3T3 
cells were seeded onto 24-well plates at 105 cells/well one day before infection. The cells 
were infected with pseudo-typed lentiviral vector with Polybrene at 8 µg/ml. The culture 
medium was changed to fresh medium after 1 day. At 3 days post infection, green fluorescent 
protein (GFP) expression was analyzed by flow cytometry using an Attune flow cytometer 
(Thermo Fisher Scientific). 
Distribution of VLPs in vivo 
The experiments were conducted with the approval of the Animal Care and Use Committee 
of the Research Institute for Microbial Diseases, Osaka University. Then, 40 µg of VLP or 
E3VLP was intravenously administered into the tail veins of 6-week-old female BALB/c 
mice in a volume of 200 µl of PBS. After the indicated time points, mice were sacrificed, and 
the spleens were removed and processed for cryo-sections as described previously 85,86. 
Cryosections (6 µm) were fixed with 4% paraformaldehyde in PBS (pH 7.2) at 4°C for 5 min, 
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blocked with StartingBlock blocking buffer (Thermo Fisher Scientific) for 10 min, and then 
sequentially incubated with primary antibodies and fluorescent-dye-conjugated secondary 
antibody and streptavidin. Three independent experiments (n = 5, 10, and 12) were 
performed. The antibodies and reagents used for staining were as follows: rat anti-
mouse/human GL7 (phycoerythrin conjugated, GL7; BioLegend), rat anti-mouse MARCO 
(phycoerythrin conjugated, ED31; Bio-Rad Laboratories), rat anti-mouse CD169 (biotin 
conjugated, MOMA-1; BMA Biomedicals), rabbit anti-CHIKV antiserum and goat anti-
rabbit IgG (fluorescein isothiocyanate conjugated; Sigma-Aldrich), and streptavidin (brilliant 
violet 421; BioLegend). Whole-section four-color fluorescent images were obtained with 
tiling options by Olympus IX83 inverted microscope system with a DP80 digital camera and 
a 10objective lens (UPlanFLN, NA 0.30; Olympus, Tokyo, Japan). All data were acquired 
and analyzed by using cellSens Dimension software (Olympus). 
Immunizations and measurement of anti-CSP antibody titer.  
Immunization and serum sample preparation were conducted at Bioqual, Inc. (Rockville, 
MD, USA). Female BALB/c mice were purchased from Harlan, and male and female Indian-
origin rhesus macaques were purchased from PrimGen. Mice were 7 to 11 weeks old and 
rhesus macaques were 5 to 8 years old at the time of the experiments. All animal experiments 
were conducted once under Institutional Animal Care and Use Committee-approved and 
Office of Laboratory Animal Welfare-assured conditions. Serum was collected from 
individual animals, and the anti-CSP repeat antibody titer was measured by ELISA. The 
ELISA plates were coated overnight with (NANP)6 peptides for P. falciparum or 
(QGPGAP)4 peptides for P. yoelii at 100 ng/well. Plates were blocked with 5% skim milk 
solution for 1 h. Samples were serially diluted in 5% skim milk and incubated in coated wells 
for 1 h, followed by 1 h of incubation with HRP-conjugated goat anti-mouse or anti-monkey 
antibody (Santa Cruz Biotechnology). Wells were developed using SureBlue TMB microwell 
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peroxidase substrate (KPL) and read on a microplate reader (BioTek). The endpoint titers of 
serum antibodies against (NANP)6 peptides or (QGPGAP)4 peptides were determined as the 
serum dilution that gives an optical density of 3 standard deviations above the negative 
control. The serum samples collected from VLPM01-immunized monkeys were also 
evaluated at the Walter Reed Army Institute of Research (WRAIR) International Reference 
Center for Malaria Serology (Silver Spring, MD, USA). Anti-NANP antibody ELISA titers 
were measured by using anti-human IgG-HRP as a secondary antibody. The antibody titers 
were initially defined as the serum dilution yielding an optical density of 1.0 in a 
standardized assay and then converted to g/ml concentrations. The investigators were not 
blinded to allocation of samples during these experiments and outcome assessment. 
Electron microscopy, cryo-EM, and image analysis.  
The morphologies of HBc-NANP VLPs and ferritin-NANP nanoparticles were analyzed at 
the Johns Hopkins School of Medicine Microscope Facility (Baltimore, MD, USA). Briefly, 
the VLPs were fixed in 4% formaldehyde, and fixed samples were placed on glow-
discharged carbon-coated 200-mesh copper grids. The grids were then stained with 1% 
phosphotungstic acid and visualized by Philips CM120 transmission electron microscopy at 
80 kV with an AMT XR80 8 megapixel camera. For the cryo-EM analysis of VLPM01, 
aliquots of 2.5 µl of sample at a 3- g/ml concentration were loaded on glow-discharged C-
Flat grids (CF-2/2-4C-50). These grids were blotted for 5 s and flash frozen in liquid ethane 
using a Gatan CP3 plunge freezer. The grids were viewed using the Purdue University’s FEI 
Titan Krios electron microscope operated at 300 kV. Images were recorded with a Gatan K2 
Summit detector calibrated to have a magnification of 38,461, yielding a pixel size of 0.65 Å. 
A total dose of 36 e/Å2 and an exposure time of 7.6 s were used to collect 38 movie frames. 
Fully automated data collection was implemented using LEGINON87. VLPM01 particles 
were incubated with Fab fragments of neutralizing mouse monoclonal antibody DG2 against 
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the NANP repeats at 4°C for 30 min using a stoichiometric ratio of about two Fab fragments 
per insertion site. Grids were prepared as described for VLPM01, and images were recorded 
under the same conditions. A total of 2,800 particles each of VLPM01 and VLPM01 
complexed with DG2 were boxed using the EMAN2 package88. MOTIONCORR software89 
was used to correct the beam-induced motion. Contrast transfer function parameters were 
estimated using CTFFIND390. The 2D classifications were performed using RELION91, and 
the 3D reconstructions were performed using jspr software92. The final reconstructions were 
estimated to be 11 and 12 Å, respectively, based on the gold-standard Fourier shell 
correlation criterion of 0.14393. Both maps were low-pass filtered to a 20-Å resolution. Both 
maps have been deposited in the Electron Microscopy Data Bank (www.emdatabank.org) 
under EMDB accession codes EMD-8424 and EMD-8425, respectively. 
Passive transfer of immunoglobulin and challenge in mice 
Five- to eight-week-old female C57BL/6 mice were purchased from the National Cancer 
Institute (Fredrick, MD, USA) and housed in the animal care facility at Johns Hopkins 
University. All procedures were performed in accordance with the National Institutes of 
Health standards, as set in the Guide for the Care and Use of Laboratory Animals. Mice were 
sorted into different groups and injected intravenously with control or VLPM01-immunized 
monkey serum (450 µl/mouse) and immediately challenged intravenously with 2,000 P. 
berghei transgenic sporozoites expressing the full P. falciparum CSP. The serum samples 
were coded, and the experiment was conducted by investigators blinded to the group 
allocation. The VLPM01-immunized monkey serum was collected weekly between weeks 5 
and 8 from a monkey injected with 45 µg of VLPM01 with alum twice and pooled. After 40 
h, the livers were harvested, and RNA was isolated to quantify the P. berghei-specific 18S 
rRNA level by qPCR as previously described94. 
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 Mouse malaria challenge model. Six- to eight-week-old female BALB/c mice were 
immunized intramuscularly with 20 µg of control VLP or Dual-PyCSP with alum adjuvant 
(Alhydrogel; Sergeant Adjuvants, Clifton, NJ) on days 0 and 21. Serum anti-PyCSP repeat 
antibody titer was measured by ELISA using (QGPGAP)4 peptide on day 33, and mice were 
challenged with infectious P. yoelii sporozoites intravenously on day 35. Cryopreserved P. 
yoelii sporozoites were purchased from Sanaria, Inc. (Rockville, MD, USA), thawed 
immediately prior to challenge, and diluted according to instructions provided by Sanaria in 
order to deliver a challenge dose of 1,000 sporozoites/animal. Parasitemia was determined on 
day 7 and day 14 post challenge by using a Giemsa-stained thin blood smear procedure. The 
investigators were blinded to allocation during the outcome assessment. Furthermore, 14 days 
after the challenge, blood was collected, and DNA was extracted by using a DNeasy blood 
and tissue kit (Qiagen) and subjected to PCR analysis. Infection was determined by 
amplifying P. yoelii-specific 18S rRNA, and the mouse glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) gene was amplified as an internal control. The primers used were 
as follows: P. yoelii 18S rRNA, 5=-ACATGGCTATGACGGGTAACG and 5= 
CCTTCCTTAGATGTGGTAGCTATTTCTC; mouse GAPDH, 5=-
ACCACAGTCCATGCCATCAC and 5=-TCCACCACCCTGTTGCTGTA. PCR products 
were resolved on 2% agarose gels and visualized with SYBR Safe DNA gel stain (Thermo 
Fisher Scientific). 
Animal studies and statistical analysis 
No statistical methods were used to predetermine animal sample size. The samples sizes were 
chosen empirically to determine whether there were differences between samples. The 
experiments were not randomized. No animals were excluded from analysis. Statistical 
analyses were performed using Prism (GraphPad Software). A Student t test was used for 
pairwise comparisons, and one-way analysis of variance (ANOVA) with Dunnett’s multiple 
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comparison test was used for comparisons across multiple groups. For the quantitative 
analysis of VLP staining in mouse spleen, a Mann-Whitney U test was used. All statistical 
tests were two-tailed. P values of 0.05 were considered statistically significant. 
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Conclusions 
 In this thesis, I reported the VLP-based vaccine development and its application as the 
platform for displaying antigens. In chapter 1, I showed that low DENV VLP yield can be 
overcome by introducing an amino acid mutation in fusion loop structure with C-terminal 
sequence modification. These modifications made VLP-based dengue vaccine industrially 
realistic. Immunization of tetravalent DENV VLP vaccine elicited strong neutralizing 
antibodies against all serotypes of DENV in mice. In the upcoming study, the efficacies of 
DENV VLP vaccine in non-human primates will be evaluated. Overall, these data 
demonstrate proof-of concept that we have a potent tetravalent DENV VLP vaccine. And in 
chapter 2, I created the novel VLP platform ‘E3αVLP’ that mimics immature form of 
alphavirus, and showed its unique features including enhanced residence time in vivo and 
immunogenicity against inserted epitope. 
 VLPs are particle structures that mimic the organization and conformation of 
authentic native virus. When it was immunized as vaccine, VLPs are highly immunogenic 
and safe because they lack the viral genome. There have been a handful of VLP-based 
vaccines in marked against; hepatitis B virus (Engerix®/GlaxoSmithKline, Recombivax 
HB®/Merck and Co) and human papillomavirus (Cervarix®/GlaxoSmithKline)57. Many 
other VLP- based vaccine, like it against influenza virus or CHIKV are in clinical trials57. 
Those success shows the potency of VLPs as vaccine. VLPs are also useful as highly 
proficient tools for displaying antigens because their repetitive surface patterns and 
particulate structure induce potent immune responses. The potential applications of VLP are 
very broad and seem promising to serve as an important next generation of vaccines. 
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